Teva suspends production at plant near Budapest
Wikimedia Commons / Raysonho @ Open Grid Scheduler / Grid Engine - Own work
Israeli-owned drugmaker Teva voluntarily suspended production at its plant in Gödöllő, on the outskirts of Budapest, in January, following observations by the United States Food and Drug Administration (FDA), Hungaryʼs National Drug and Food Health Institute (OGYEI) said on Friday, according to Hungarian news agency MTI.
The production was suspended following a routine inspection of Tevaʼs plant on January 21-29, OGYEI said.
The FDA announced an alert on May 27 prohibiting drugs made at the plant from entering the United States.
OGYEI is scrutinizing the plant and will conduct a full-scale audit in August. Until production is re-launched, OGYEI will closely monitor inventories.
OGYEI director Csilla Pozsgay said the available information suggests the FDA was concerned about production circumstances rather than the safety of products on the market.
The OGYEI will do everything in its power to support the re-launch of production at the plant that is in compliance with regulations, the institute said.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.